Iovance Biotherapeutics IncIOVA
Price$14.23Intrinsic value$7.2349% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $325M+98.1% YoYTTM through 30 Jun 2026
Net Income -$289.5MTTM through 30 Jun 2026
Free Cash Flow -$296.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin40.5%
EBITDA Margin-88.6%
Operating Margin-113.5%
Net Margin-89.1%

Returns

-48.9%ROE
-38.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.60x
Net Debt-$313.4Mnet cash position
Cash & Equivalents$110.8M

Quality Metrics

Altman Z-Score11.41
Piotroski F-Score4 / 9
FCF Margin-91.2%
Rule of 40-68.2
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $263.5M
Diluted EPS-$0.69TTM
'19'20'21'22'23'24'25
FY2025: $-1,094.00

Dividend

No dividend

Capital Allocation

R&D Spend$267.7M
Capex Intensity9.9%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.